Completed PHASE3 INTERVENTIONAL 2-arm NCT00152230

A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)

A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of UFT Compared With Surgery Alone in Patients With Dukes C Colorectal Cancer (NSAS-CC)

Sponsor: Taiho Pharmaceutical Co., Ltd.

Conditions Colorectal Cancer

Interventions Surgery alone UFT (uracil, tegafur)

Updated 5 times since 2017 Last updated: Jul 6, 2011 Started: Oct 31, 1996 Primary completion: Mar 31, 2006 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Colorectal Cancer, this trial is completed. The trial is conducted by Taiho Pharmaceutical Co., Ltd. and has accumulated 5 data snapshots since 1996. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Taiho Pharmaceutical Co., Ltd.

Data source: Taiho Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• 6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan